Comparative Pharmacology
Head-to-head clinical analysis: TAGAMET HB versus TAGAMET HB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAGAMET HB versus TAGAMET HB 200.
TAGAMET HB vs TAGAMET HB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H2 receptors, inhibiting gastric acid secretion by blocking the action of histamine on parietal cells in the stomach.
Competitive antagonist at histamine H2-receptors, inhibiting gastric acid secretion by blocking histamine-mediated stimulation of parietal cells.
200-400 mg orally twice daily or 800 mg orally at bedtime.
200 mg orally once or twice daily, not to exceed 400 mg per day.
None Documented
None Documented
2–3 hours (normal renal function), prolonged to 5–6 hours in moderate renal impairment, up to 20 hours in severe impairment; requires dose adjustment in CrCl <30 mL/min.
Terminal elimination half-life: 2-3 hours in patients with normal renal function. In elderly or renal impairment, half-life may extend to 4-5 hours.
Renal (70% unchanged via glomerular filtration and tubular secretion), fecal (less than 10%), biliary (minor).
Renal: 75-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: ~20% as metabolites and unchanged drug.
Category C
Category C
H2 receptor antagonist
H2 receptor antagonist